Posted in | News | Medical Robotics

Medrobotics Announces Completion of Series D Financing

Medrobotics Corp., an emerging medical robotics company developing the innovative Flex™ Robotic System, announced today the conversion of notes totaling $33.6 Million purchased through recent financings into Series D Preferred Stock.

Existing Medrobotics shareholders and undisclosed new investors participated in the Series D raise. Proceeds will be used for regulatory preparations and submissions and for anticipated commercial launches next year in Europe and the United States.

“Patients, surgeons, and hospitals will all benefit from the Flex Robotic System’s enabling minimally invasive surgical technology,” said Samuel Straface, Ph.D., president and CEO of Medrobotics. “The Flex Robotic System will provide transoral single-site access and visualization for surgery in hard-to-reach locations in the throat and voice box. Minimally invasive surgery has been shown to be more cost-effective and less painful for the patient and also leads to quicker hospital discharge and faster recovery.”

The Flex Robotic System is anticipated to provide a cost‐effective, robot-assisted surgical platform for hospitals and surgeons eager to expand their offering of minimally invasive treatment options. In addition to ENT, the platform is being developed for several other single-site access surgical applications with difficult-to-reach anatomies.

Source: Medrobotics Corp.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.